Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin Substitution in Intensive Phase of Pulmonary Tuberculosis Treatment
NCT04187469Unknown
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2020
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of moxifloxacin in pulmonary tuberculosis (TB) (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Rate of adverse outcomes at 18 months. Status: unknown.
02
Drugs
moxifloxacin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT04187469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187469.